News MS Society of Canada Urges Consistent Access to COVID-19 Boosters MS Society of Canada Urges Consistent Access to COVID-19 Boosters by Patricia Inacio, PhD | November 19, 2021 Share this article: Share article via email Copy article link The Multiple Sclerosis Society of Canada is urging that all provinces and territories in Canada offer COVID-19Ā booster vaccines to at-risk populations, including people who are moderately to severely immunocompromised and multiple sclerosis (MS) patients. In letters sent earlier this month, in collaboration with 11 other health charities, the MS Society asked that rules for access to a third dose of a COVID-19 vaccine should be made clear and implemented across all jurisdictions. According to aĀ press release, āAll Canadians who are immunocompromised have the right to clearly understand whether they are eligible for a third dose of the COVID-19 vaccine to achieve an adequate level of protection.ā Recommended Reading November 11, 2021 News by Marta Figueiredo, PhD North American MS Societies Targeting Earliest MS Predictors The appeal, which is supported by the Canadian Network of MS Clinics, follows the latest recommendations by the countryās National Advisory Committee on Immunization (NACI) stating that booster doses may be offered to people 70 and older, people living in care homes, frontline healthcare workers, and people with health conditions that put them at higher risk, such as MS. Also, it comes in response to reported differences across provinces and territories in Canada regarding access to a third dose of a vaccine. According to the Society, this leads to āconfusion and increased risk for vulnerable Canadians.ā Booster shots are meant to sustain the protection against COVID-19 provided by the initial vaccine dose(s), which slightly weakens over time, particularly in older people. This extra protection likely will be important for the winter months, when the risk of infections and hospitalizations are likely to increase, the Society noted. The NACI recommends a booster with either Pfizer-BioNTech or the Moderna mRNA vaccines. Immunomodulatory and immunosuppressiveĀ disease-modifying therapies (DMTs)Ā ā the mainstay of MS treatment ā generally work by suppressing the immune system to dampen the abnormal immune responses that drive nerve cell damage in MS. This may limit the immune systemās ability to fight viruses like SARS-CoV-2, the one causing COVID-19, which then increases the chances of severe disease. In a previous letter, sent in August to the NACI and all provinces and territories, the Society requested additional COVID-19 booster shots for people treated with DMTs that may weaken their immune system. NACI updated its recommendations to include immunocompromised people as eligible to receive a third booster shot in September. This is in agreement with guidelines issued by the U.S. Food and Drug Administration to include people on DMTs to receive booster vaccines for COVID-19. Print This Page About the Author Patricia Inacio, PhD Patricia holds her PhD in cell biology from the University Nova de Lisboa, Portugal, and has served as an author on several research projects and fellowships, as well as major grant applications for European agencies. She also served as a PhD student research assistant in the Department of Microbiology & Immunology, Columbia University, New York, for which she was awarded a Luso-American Development Foundation (FLAD) fellowship. Tags COVID-19, immunocompromised, Multiple Sclerosis Society of Canada, recommendations
March 28, 2024 Columns by Benjamin Hofmeister Multiple sclerosis awareness is for people with MS, too
March 28, 2024 News by Lindsey Shapiro, PhD Restoring ‘lost’ pathway of neuroprotection benefits MS mice